We are live on ! Find out more
ICPT

Intercept Pharmaceuticals, Inc.

Delisted

ICPT was delisted on the 7th of November, 2023.

200 hedge funds and large institutions have $5.01B invested in Intercept Pharmaceuticals, Inc. in 2015 Q1 according to their latest regulatory filings, with 54 funds opening new positions, 78 increasing their positions, 53 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

135% more first-time investments, than exits

New positions opened: 54 | Existing positions closed: 23

107% more capital invested

Capital invested by funds: $2.42B → $5.01B (+$2.58B)

47% more repeat investments, than reductions

Existing positions increased: 78 | Existing positions reduced: 53

18% more funds holding

Funds holding: 169200 (+31)

14% more call options, than puts

Call options by funds: $257M | Put options by funds: $225M

Holders
200
Holders Change
+31
Holders Change %
+18.34%
% of All Funds
5.33%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.08%
New
54
Increased
78
Reduced
53
Closed
23
Calls
$257M
Puts
$225M
Net Calls
+$31.7M
Net Calls Change
+$71.9M
Name Holding Trade Value Shares
Change
Change in
Stake
Point72 Asset Management
26
Point72 Asset Management
Connecticut
$37.3M -$36.4M -167,900 -56%
UBS AM
27
UBS AM
Illinois
$36.2M +$1.32M +6,100 +5%
Norges Bank
28
Norges Bank
Norway
$36.1M +$1.1M +5,072 +4%
BA
29
BlackRock Advisors
Delaware
$34.2M +$25.8M +118,978 +5,594%
Adage Capital Partners
30
Adage Capital Partners
Massachusetts
$31.6M -$1.74M -8,025 -7%
Morgan Stanley
31
Morgan Stanley
New York
$29.3M -$1.21M -5,569 -5%
Citadel Advisors
32
Citadel Advisors
Florida
$29.2M +$21.8M +100,573 +3,480%
MAA
33
Managed Account Advisors
New Jersey
$27M +$20M +92,535 +2,783%
Bank of America
34
Bank of America
North Carolina
$25.2M +$2.84M +13,094 +17%
Massachusetts Financial Services
35
Massachusetts Financial Services
Massachusetts
$24.9M +$430K +1,986 +2%
FCM
36
Farallon Capital Management
California
$24.1M +$18.5M +85,600 New
Geode Capital Management
37
Geode Capital Management
Massachusetts
$21.1M +$2.25M +10,406 +16%
Lord, Abbett & Co
38
Lord, Abbett & Co
New Jersey
$20.4M +$15.7M +72,428 New
Axa
39
Axa
France
$19.3M +$1.66M +7,674 +13%
CS
40
Credit Suisse
Switzerland
$18.5M +$2.02M +9,324 +17%
EA
41
Emerald Advisers
Pennsylvania
$18.2M +$166K +765 +1%
TCIM
42
TIAA CREF Investment Management
New York
$17.2M +$4.8M +22,144 +57%
Bank of New York Mellon
43
Bank of New York Mellon
New York
$16.5M +$3.02M +13,958 +31%
Citigroup
44
Citigroup
New York
$16M +$5.99M +27,668 +96%
CC
45
Cannell & Co
New York
$15.7M +$12M +55,580 New
Artisan Partners
46
Artisan Partners
Wisconsin
$15.5M +$5.4M +24,932 +83%
Northern Trust
47
Northern Trust
Illinois
$14.9M +$1.25M +5,767 +12%
CCMU
48
Cheyne Capital Management (UK)
United Kingdom
$13.9M +$2.25M +10,405 +27%
CS
49
Candriam SCA
Luxembourg
$13.8M +$3.03M +14,000 +40%
ICAP
50
Independence Capital Asset Partners
Colorado
$13.8M +$10.6M +48,934 New

ICPT Hedge Fund Activity: Q1 2015 in Review

200 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Intercept Pharmaceuticals, Inc. (ICPT) for Q1 2015, worth a combined $5.01B — up 107% from $2.42B a quarter earlier.

Buyers outnumbered sellers: 54 funds opened new ICPT positions and 23 closed out — a net gain of 31 holders — while 78 added to existing stakes and 53 trimmed.

The largest buyer was Ameriprise, adding an estimated $161M. The largest seller was OrbiMed, cutting an estimated $79M.

  • 200 institutional investors held Intercept Pharmaceuticals, Inc. (ICPT) as of Q1 2015, up from 169 in Q4 2014.
  • Funds reported $5.01B of Intercept Pharmaceuticals, Inc. stock for Q1 2015, up 107% quarter-over-quarter.
  • 54 funds opened new Intercept Pharmaceuticals, Inc. positions in Q1 2015 and 23 closed out, a net change of +31 holders.
  • The largest Intercept Pharmaceuticals, Inc. buyer in Q1 2015 was Ameriprise, an estimated $161M added.
  • The largest Intercept Pharmaceuticals, Inc. seller in Q1 2015 was OrbiMed, an estimated $79M sold.

Based on aggregated 13F filings for Q1 2015.